Atypical Hemolytic Uremic Syndrome
Information
- Disease name
- Atypical Hemolytic Uremic Syndrome
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00838513 | Completed | Phase 2 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS) | July 2009 | December 2013 |
| NCT00844428 | Completed | Phase 2 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS | July 2009 | December 2013 |
| NCT00844545 | Completed | Phase 2 | Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS | May 2009 | July 2013 |
| NCT00844844 | Completed | Phase 2 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS | May 2009 | July 2013 |
| NCT02574403 | Completed | Phase 4 | Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS | November 2015 | December 3, 2019 |
| NCT03518203 | Completed | Phase 2 | Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients | August 3, 2018 | June 1, 2022 |
| NCT04749810 | Completed | Observational Study of Elizaria® in aHUS Patients | December 19, 2019 | April 30, 2022 | |
| NCT05935215 | Recruiting | Phase 3 | Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | February 28, 2024 | July 21, 2029 |
| NCT05996731 | Recruiting | N/A | Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases | February 21, 2024 | September 2025 |
| NCT06065852 | Recruiting | National Registry of Rare Kidney Diseases | November 6, 2009 | December 31, 2039 | |
| NCT04861259 | Recruiting | Phase 3 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | October 22, 2021 | December 7, 2029 |
| NCT04889430 | Recruiting | Phase 3 | Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy | January 17, 2022 | January 6, 2026 |
| NCT04958265 | Recruiting | Phase 3 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | November 17, 2021 | September 16, 2029 |
| NCT05795140 | Recruiting | Phase 3 | Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS | May 8, 2024 | January 3, 2033 |
| NCT05805202 | Recruiting | N/A | Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy | April 6, 2023 | March 2025 |
| NCT01793168 | Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford | July 2010 | December 2100 | |
| NCT01522170 | Terminated | aHUS Observational Long Term Follow-Up | March 2012 | January 2017 | |
| NCT02614898 | Terminated | Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment | November 4, 2015 | October 5, 2017 | |
| NCT02464891 | Terminated | Phase 2 | Complement Inhibition in aHUS Dialysis Patients | June 4, 2015 | July 13, 2017 |
| NCT03574506 | Unknown status | Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series | April 15, 2018 | November 30, 2020 | |
| NCT03605511 | Unknown status | TTP and aHUS in Complicated Pregnancies | September 21, 2018 | March 14, 2020 | |
| NCT03205995 | Unknown status | Phase 3 | Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome | February 23, 2017 | February 2020 |
| NCT03999840 | Withdrawn | Phase 2 | Eculizumab to Cemdisiran Switch in aHUS | January 2021 | March 2024 |
| NCT02626663 | Withdrawn | The Role of Microparticles as a Biomarker | July 2016 | December 2022 | |
| NCT03303313 | Withdrawn | Phase 2 | A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome | September 19, 2017 | September 12, 2018 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D065766